| NCT ID | NCT06845371 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Tuebingen |
| Condition | Congenital Heart Disease (CHD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 845 participants |
| Start Date | 2026-04-01 |
| Primary Completion | 2027-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 845 participants in total. It began in 2026-04-01 with a primary completion date of 2027-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Extension of the MELODY Registry, to assess longterm follow-up clinical results of Melody valve implantation after its commercialization in Europe / OUS
Eligibility Criteria
Inclusion Criteria: * previous inclusion in the MELODY Registry Exclusion Criteria: * none
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06845371 clinical trial?
This trial is open to participants of all sexes, studying Congenital Heart Disease (CHD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06845371 currently recruiting?
Yes, NCT06845371 is actively recruiting participants. Contact the research team at Johannes.Nordmeyer@med.uni-tuebingen.de for enrollment information.
Where is the NCT06845371 trial being conducted?
This trial is being conducted at Tübingen, Germany.
Who is sponsoring the NCT06845371 clinical trial?
NCT06845371 is sponsored by University Hospital Tuebingen. The trial plans to enroll 845 participants.